Last reviewed 2026-04-22 · How we verify

DWP14012 A mg

DWP14012 is a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases incretin hormone levels to improve blood glucose control in type 2 diabetes.

DWP14012 is a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases incretin hormone levels to improve blood glucose control in type 2 diabetes. Used for Type 2 diabetes mellitus.

At a glance

Mechanism of action

DPP-4 inhibitors work by blocking the enzyme that degrades glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), thereby prolonging their action. This leads to increased insulin secretion in response to meals and decreased glucagon secretion, resulting in improved glycemic control with a low hypoglycemia risk.

Approved indications

• Type 2 diabetes mellitus

Common side effects

• Nasopharyngitis
• Headache
• Upper respiratory tract infection

Key clinical trials

• Study to Evaluate the Efficacy and Safety of DWP14012-based Triple Therapy in Eradication of Helicobacter Pylori (PHASE3)
• Study to Evaluate the Safety/Tolerability, PK and PD After Intravenous DWJ1521 Administration in Healthy Volunteers (PHASE1)
• Study to Evaluate the Efficacy and Safety of DWP14012 in Prevention of NSAIDs Induced Peptic Ulcer (PHASE3)
• to Evaluate the Safety/Tolerability and Pharmacokinetics, and Pharmacodynamics of DWP14012 Injection (PHASE1)
• A Clinical Study to Investigate the Mass Balance and Biotransformation of [14C]DWP14012 in Healthy Chinese Male Subjects (PHASE1)
• Phase 1 Clinical Trial to Evaluate the Effect of DWP14012 on the Pharmacokinetics of DWC202201 in Healthy Subjects (PHASE1)
• Study to Evaluate the Efficacy and Safety of DWP14012 in Patients With Acute or Chronic Gastritis (PHASE3)
• Treatment Effect According to Timing of Administration of DWP14012 40 mg (NA)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.